A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
12/2002
12/04/2002	EP1261316A2 Improvements in or relating to the delivery of oral drugs
12/04/2002	EP1158962B1 Method for producing solid dosage forms containing cyclodextrin
12/04/2002	EP1109529B1 Use of a lipid extract of the skeletonema algae
12/04/2002	EP1102601A4 Targeting and prolonging association of drugs to the luminal surface of the pulmonary vascular endothelial cells
12/04/2002	EP1073417B1 Pharmaceutical aerosol formulation
12/04/2002	EP0939638B1 Injectable formulations of avermectins and milbemycins
12/04/2002	EP0929234B1 Tablets containing a sweetening mixture
12/04/2002	EP0925060B1 Fast decomposing pellets
12/04/2002	EP0873114B1 Granulates for cosmetic and pharmaceutical preparations
12/04/2002	EP0850046B1 Microemulsions for use as vehicles for administration of active compounds
12/04/2002	EP0821582B1 Controlled release tablet
12/04/2002	EP0820306B1 Pharmaceutical composition containing pectin and a phospholipid, used as an antidiarrheal and antiulcer agent
12/04/2002	EP0783324B1 Cellular immunity-inducing conjugate
12/04/2002	EP0781135B1 Codeine containing formulations
12/04/2002	EP0750495B1 Use of a lipophilic surfactant in a pharmaceutical composition
12/04/2002	EP0740548B1 Drug targeting system, method for preparing same and its use
12/04/2002	CN1383450A Antibody molecules having specificity for huamn tumor necrosis factory alpha, and use thereof
12/04/2002	CN1383382A Use of methoxymorpholino dexorubicin for treatment of liver tumor
12/04/2002	CN1383379A Method of treatment of seborrheic dermatitis
12/03/2002	US6489369 Insoluble or sparingly water soluble drugs such as etoposide, paclitaxel, propofol or cyclosporins, biodegradable/ -compatible sterol solubilizers, carriers and diluents having storage stability
12/03/2002	US6489367 Semifluorinated alkanes and the use thereof
12/03/2002	US6489363 For therapy of sleepiness, tiredness, parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, attention deficit hyperactivity disorder, cognitive dysfunction or fatigue, stimulation of appetite
12/03/2002	US6489358 Pharmaceutical compositions containing mupirocin
12/03/2002	US6489346 Substituted benzimidazole dosage forms and method of using same
12/03/2002	US6489304 Operable association (such as amide, ester or disulfide bond) between a hyperstructure forming unit and an effector unit such as a nucleotide; drug delivery for gene therapy, antisense therapy for example
12/03/2002	US6489303 Anthelmintic composition
12/03/2002	US6489302 Of varous drugs (such as anticancer agents) that make use of glucose transporter to deliver drugs to site of action (such as across blood-brain barrier) more efficiently, thereby reducing side effects
12/03/2002	US6488965 Synergistic antimicrobial preparations containing chlorite and hydrogen peroxide
12/03/2002	US6488964 Process for manufacturing coated gabapentin or pregabalin particles
12/03/2002	US6488962 Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
12/03/2002	US6488953 Oral transmucosal delivery
12/03/2002	US6488952 Semisolid therapeutic delivery system and combination semisolid, multiparticulate, therapeutic delivery system
12/03/2002	US6488943 Anionic surfactant; proton donating agent comprising 2-pyrrolidone-5 carboxylic acid
12/03/2002	US6488928 Product for topical application containing a lipase and a hydroxy acid precursor
12/03/2002	US6488665 Antimicrobial alcohol gel pre-operative skin-preparation delivery system
12/03/2002	US6488164 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
12/03/2002	CA2259343C Novel radiopharmaceutical compositions and matrices and uses thereof
12/03/2002	CA2253061C A novel anti-allergy anti-inflammatory composition
12/03/2002	CA2204475C Pharmaceutical composition containing stabilized lipophilic matrices for the controlled release of active substances
12/03/2002	CA2126103C Transfection of lung via aerosolized transgene delivery
12/03/2002	CA2116478C Prolonged delivery of peptides
12/03/2002	CA2095789C Transdermal administration system for estradiol
12/03/2002	CA2060544C Recombinant antibodies specific for a growth factor receptor
12/03/2002	CA2039773C Cosmetic composition or aqueous dermo-pharmaceutical containing a suspension of hydrophile lipidic substance hydrated
12/03/2002	CA2021580C Polysiloxane-grafted copolymer topical binder composition with novel fluorochemical comonomer and method of coating therewith
11/2002
11/30/2002	CA2389560A1 Cosmetic and/or dermatological and/or pharmaceutical compound for topical application, containing at least one 3 beta-hydroxysteroid dehydrogenase enzyme inhibitor
11/30/2002	CA2388169A1 Phospholipid composition and use of same
11/30/2002	CA2387821A1 Azalide antibiotic compositions
11/28/2002	WO2002095391A1 Methods and formulations for increasing the affinity of a1 adenosine receptor ligands for the a1 adenosine receptor
11/28/2002	WO2002095043A1 Cellular signal-responsive gene transcriptional regulation system
11/28/2002	WO2002095027A2 Immunostimulatory oligodeoxynucleic molecules
11/28/2002	WO2002095022A2 Sequence-specific dna binding compounds and their use in targeting telomeres and other dna sequences
11/28/2002	WO2002095007A2 Conjugates activated by cell surface proteases and therapeutic uses thereof
11/28/2002	WO2002095005A2 Therapeutic dna vaccination
11/28/2002	WO2002094879A1 Antibodies specific for cd44v6
11/28/2002	WO2002094845A2 Method for stabilising of nucleic acids
11/28/2002	WO2002094774A2 Oxcarbazepine dosage forms
11/28/2002	WO2002094376A2 Compositions and methods for promoting or inhibiting ndpk
11/28/2002	WO2002094342A2 Compositions for protein delivery via the pulmonary route
11/28/2002	WO2002094325A2 Cytotoxic cd44 antibody immunoconjugates
11/28/2002	WO2002094324A1 Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
11/28/2002	WO2002094323A1 Weight reduction or weight controlling composition
11/28/2002	WO2002094316A2 Method of preparing aluminium-hydroxide gel
11/28/2002	WO2002094288A1 Veterinary compositions comprising avermectin-oxime derivatives and praziquantel
11/28/2002	WO2002094285A1 Single-daily-dose antidiabetic oral pharmaceutical form comprising a biguanide and at least another active principle
11/28/2002	WO2002094271A1 Targeted delivery of bioaffecting compounds for the treatment of cancer
11/28/2002	WO2002094257A1 Analgesic/antiinflammatory patches for topical use
11/28/2002	WO2002094248A2 Composition and use of substances for stabilising amino acids containing sulphur and/or for inhibiting the continuous formation of amino acids containing sulphur in a blood sample
11/28/2002	WO2002094242A1 Delivery of rizatriptan or zolmitriptan through an inhalation route
11/28/2002	WO2002094236A1 Delivery of antipsychotics through an inhalation route
11/28/2002	WO2002094231A1 Delivery of analgesics through an inhalation route
11/28/2002	WO2002094227A1 Controlled release drug delivery device
11/28/2002	WO2002094225A1 Granular preparations of gaboxadol
11/28/2002	WO2002094221A1 Emulsion and dispersion formulations and method
11/28/2002	WO2002094220A1 Liquid pharmaceutical composition
11/28/2002	WO2002094218A2 Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
11/28/2002	WO2002094215A2 Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vimyl acetate as surface stabilizers
11/28/2002	WO2002094200A2 Pulmonary administration of chemically modified insulin
11/28/2002	WO2002094179A2 Novel topical microbicidal compositions
11/28/2002	WO2002094173A2 Tamper resistant oral dosage form
11/28/2002	WO2002093998A2 Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof
11/28/2002	WO2002083176A8 Biomaterials comprising a melanocyte stimulating hormone (msh), and method of forming
11/28/2002	WO2002080887A3 Timed pulse release composition
11/28/2002	WO2002080648A3 Mucosal boosting following parenteral priming
11/28/2002	WO2002072631A8 Mhc molecule constructs and their usesfor diagnosis and therapy
11/28/2002	WO2002072080A3 Paracetamol solutions which are stable in storage and ready for infusion
11/28/2002	WO2002067859A3 Ascorbic acid analogs for metalloradiopharmaceuticals
11/28/2002	WO2002011702A3 Hydrogel-driven drug dosage form
11/28/2002	WO2001089542A3 Composition for improving the cell protection comprising a lipophilic antioxidant and a hydrophilic antioxidant
11/28/2002	WO2001082897A3 Liposome drug delivery
11/28/2002	WO2001081415A3 Parathyroid hormone and parathyroid hormone-related protein antagonists
11/28/2002	WO2001035942A9 Analgesic compositions containing buprenorphine
11/28/2002	US20020177839 Microprojection array having a beneficial agent containing coating
11/28/2002	US20020177688 Genetically engineered polypeptide for use in the treatment of infections, inflammation, hematopietic, bone and wound disorders
11/28/2002	US20020177626 Comprises analgesics such as ibuprofen and diphenhydramine; storage stability
11/28/2002	US20020177624 Prevents vaginitis
11/28/2002	US20020177615 Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones
11/28/2002	US20020177611 Pharmaceutical formulation comprising glycine as a stabilizer
11/28/2002	US20020177585 Peroxidation reaction products of an alkene, such as geraniol; penetrating solvent, such as dimithyl sulfoxide; a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone.
11/28/2002	US20020177582 For diagnosing and treating urogenital disorders associated with atrophic vaginitis in symptomatic women having vaginal pH of 4.5 or above

1 ... 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 ... 1712